NCT03701802 (Kinga) is a clinical trial in HIV Infections, sponsored by University of Washington.

Who is sponsoring NCT03701802?

NCT03701802 is sponsored by University of Washington.

What condition does NCT03701802 study?

NCT03701802 studies HIV Infections, HSV-2 Infection.

Is NCT03701802 still recruiting?

NCT03701802 is currently completed. Last updated 3 November 2020.

Last reviewed 2020-11-03 · How we verify

NCT03701802: Kinga

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Immunogenetic Modulators of Mucosal Protection From HIV-1

Completed Last updated 3 November 2020

What this trial tests

trial in HIV Infections in 812 participants. Completed in 30 September 2020.

Timeline

27 September 2018

Primary endpoint
30 September 2020

30 September 2020

Quick facts

Lead sponsor	University of Washington
Status	Completed
Study type	OBSERVATIONAL
Enrollment	812
Start date	27 September 2018
Primary completion	30 September 2020
Estimated completion	30 September 2020
Sites	1 location across Kenya

Conditions studied

HIV Infections — all drugs for HIV Infections →
HSV-2 Infection — all drugs for HSV-2 Infection →

Sponsor

University of Washington

Who can join

Adults 18 to 65, any sex, with HIV Infections or HSV-2 Infection. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This is a single site, prospective, observational study that seeks to assess changes in mucosal immunity that occur as a result of HIV-1 exposure, HSV-2 infection, and/or pre-exposure prophylaxis (PrEP) usage to prevent HIV-1 acquisition. The study will collect mucosal and peripheral blood samples for a detailed analysis of longitudinal immune responses, while also obtaining samples for genetic characterization to understand how variants in CD101 and UBE2V1 may modulate host mucosal responses and HIV-1 infection risk.

Publications & conference data

2 peer-reviewed publications reference this trial (live from Europe PMC):

Bacterial vaginosis associates with dysfunctional T cells and altered soluble immune factors in the cervicovaginal tract.
MacLean F, Tsegaye AT, Graham JB, Swarts JL, et al · · 2025 · cited 5× · PMID 40131862 · DOI 10.1172/jci184609
Genital herpes shedding episodes associate with altered spatial organization and activation of mucosal immune cells.
MacLean F, Zemek RM, Tsegaye AT, Graham JB, et al · · 2026 · cited 1× · PMID 41252205 · DOI 10.1172/jci.insight.197491

Verify or expand the search:

Other recruiting trials for HIV Infections

Currently open trials in the same condition.

NCT07225530 — Implementation of Screen, Treat, and Triage for Women Living With HIV in La Romana (iSTAR) · NA · recruiting
NCT07202546 — A Phase 2b Study Evaluating Oral VH4524184 Regimens in Treatment Naïve Persons With HIV-1 (INNOVATE Study) · Phase 2 · recruiting
NCT06694753 — Safety and Immunogenicity Study of Three mRNAs Encoding HIV Immunogens in Adult Participants Without HIV and in Overall · Phase 1 · recruiting
NCT07235852 — Pilot Testing Into the Feasibility of the Developed Cognitive Behavioral Therapy Intervention · NA · recruiting
NCT06665646 — Clinical Trial to Evaluate the Safety and Immunogenicity of Hiltonol, Poly-ICLC-adjuvanted CD40.HIVRI.Env (VRIPRO) in Ad · Phase 1 · recruiting

Other University of Washington trials

Trials by the same sponsor.

NCT07430852 — Inherited and Environmental Risks Acting on Body Weight · NA · not yet recruiting
NCT07466498 — Estrogen to Improve Quality of Life for Men With Newly Diagnosed or Recurrent Metastatic Hormone Sensitive Prostate Canc · Phase 2 · not yet recruiting
NCT06422299 — Developing and Testing an Online Intervention for Alcohol and Cannabis Misuse and Healthy Relationship Skills Among Youn · NA · not yet recruiting
NCT07322341 — SX-682 and Atezolizumab for the Treatment of Advanced or Metastatic, Recurrent Non-small Cell Lung Cancer · Phase 2 · not yet recruiting
NCT07332351 — Neoadjuvant Intravesical Nadofaragene Firadenovec With Gemcitabine, Cisplatin and Durvalumab for the Treatment of Muscle · Phase 2 · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03701802 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 9 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by University of Washington
Last refreshed: 3 November 2020

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03701802.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing